AstraZeneca’s Imfinzi Squeezes Through: Is FDA Reversing Course Or In A Transition Period?

 
• By Sarah Karlin-Smith
series of doors starting with each door being more open than the last
Imfinzi's perioperative NSCLC indication got through FDA on a data set that may soon shut other sponsors out. • Source: Shutterstock

More from Post-Marketing Regulation & Studies

More from Product Reviews